
Wall Street Analysts Make Bold Moves: Upgrades, Downgrades, and New Coverage Ahead!
2025-09-16
Author: Chun
In the fast-paced world of Wall Street, analysts are reshaping the landscape with significant upgrades and downgrades. Here’s a roundup of the latest high-impact analyst calls that could shift your investment strategy!
Baidu Soars with Upgrade from Arete
Arete has flipped the script on Baidu (BIDU), upgrading it from a Sell to a Buy with a tantalizing $143 price target. The firm emphasizes that Baidu's ambitious Kunlun chip project could cushion the impact of its sluggish online advertising revenue, making this tech giant one to watch.
CoreWeave's Jump to Outperform by Citizens JMP
Citizens JMP has elevated CoreWeave (CRWV) to Outperform from Market Perform with a jaw-dropping price target of $180. Analysts forecast that this titan of graphics processing could see its business skyrocket from $3 billion to a staggering $300 billion!
Hershey’s Sweet Upgrade by Goldman Sachs
Sweet news for Hershey (HSY) as Goldman Sachs upgrades its rating from Sell to Buy, raising the price target from $170 to $222. The firm notes that shares are currently trading at an enticing risk/reward ratio after multiple guidance cuts last year.
Prologis Positioned for Success
Bank of America has raised Prologis (PLD) from Neutral to Buy, adjusting the price target to $130 from $118. Insights from their Global RE Conference suggest that lease conversions are showing promising signs, indicating heightened demand dynamics set to continue through 2026.
Union Pacific Bounces Back
Loop Capital has upgraded Union Pacific (UNP) from Sell to Hold with a new price target of $227, up from $214. Despite a 5% dip in share value this year, Union Pacific’s stock is now competitively priced, warranting consideration.
Downgrade Alert: Warner Bros. Discovery
In a cautionary tone, TD Cowen downgraded Warner Bros. Discovery (WBD) from Buy to Hold, maintaining a price target of $14. Despite a recent surge linked to rumors of a Paramount Skydance bid, analysts believe the stock's upside may be limited.
Live Nation Loses Some Luster
Rothschild & Co has downgraded Live Nation (LYV) from Buy to Neutral, now targeting $170. Analysts predict earnings potential may slow down as margin expansion dwindles following fiscal 2026.
VF Corp Faces a Reality Check
Stifel has downgraded VF Corp (VFC) from Buy to Hold, raising the price target to $16. After a robust return of 12.5% over the past month, analysts see the stock's risk-reward balance as now neutral.
Camp4 Therapeutics Takes a Hit
JPMorgan downgraded Camp4 Therapeutics (CAMP) to Neutral. Though the company secured funding through a private placement extending to 2027, their early-stage program still leaves uncertainty for investors.
Neumora Therapeutics Downgraded After Trial Setback
Also from JPMorgan, Neumora Therapeutics (NMRA) has been downgraded to Underweight following a disappointing result in their Phase 3 trial for treating major depressive disorder, which didn’t meet key endpoints.
Apple and IT Hardware Companies Hit the Radar
Bernstein has initiated coverage of key players in the IT hardware space, including Apple (AAPL), with all four firms—Apple, Dell Technologies, Seagate, and SanDisk—earning Outperform ratings. Analysts foresee a bright future driven by AI growth sparking sustainable increases in spending.
Klarna Gains Favor with Compass Point
Compass Point has given Klarna (KLAR) a Buy rating with a $53 price target, suggesting a 24% upside. Their assessment reflects ongoing robust demand in the buy-now-pay-later sector.
CoreWeave Gains New Praise
Raymond James initiated coverage of CoreWeave (CRWV) with an Outperform rating and a $130 price target, underscoring strong growth potential as AI technology advances.
Kingsoft Cloud Enters the Spotlight
Deutsche Bank has initiated a Buy rating for Kingsoft Cloud (KC) with a $21 target, citing its leading position in the Chinese cloud market and potential explosive growth fueled by AI demand.
TransMedics Gets Positive Coverage
Evercore ISI has given TransMedics (TMDX) an Outperform rating and a $155 price point, suggesting investors should reconsider their assumptions as operational costs align more closely with competitors.
With these major updates, investors should keep a close eye on market movements and analyst recommendations to inform their next moves!